Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Recurrent Ovarian Cancer
NCT02560337Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Sep 2015
- Primary completion
- Dec 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in ovarian cancer, sponsored by Vejle Hospital. Primary endpoint: Number of patients alive and without progression after three months of treatment at 3 months. Started Sep 2015; status: completed.
02
Drugs
cabazitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02560337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560337.